The moment Athenex executives and investors have been waiting for is almost here


Results from the Phase 3 study of Athenex's leading drug candidate will be published in the middle of this year, potentially signaling to the world the arrival of its technology.

Previous State watchdog points to insulin spending as health care cost driver
Next Moody's downgrades Einstein's debt rating